Carl V Hamby

Summary

Affiliation: New York Medical College
Country: USA

Publications

  1. ncbi request reprint Expression of a catalytically inactive H118Y mutant of nm23-H2 suppresses the metastatic potential of line IV Cl 1 human melanoma cells
    C V Hamby
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Int J Cancer 88:547-53. 2000
  2. pmc Use of Peptide library screening to detect a previously unknown linear diagnostic epitope: proof of principle by use of lyme disease sera
    Carl V Hamby
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Clin Diagn Lab Immunol 12:801-7. 2005
  3. pmc SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model
    Rachel Ackerman
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Toxins (Basel) 2:2242-57. 2010

Research Grants

Detail Information

Publications3

  1. ncbi request reprint Expression of a catalytically inactive H118Y mutant of nm23-H2 suppresses the metastatic potential of line IV Cl 1 human melanoma cells
    C V Hamby
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Int J Cancer 88:547-53. 2000
    ..These results imply that bound NDPK B promotes metastasis and suggest that inhibition of its function or of its binding to critical sites may be a useful approach to limit the development of metastases in human melanoma...
  2. pmc Use of Peptide library screening to detect a previously unknown linear diagnostic epitope: proof of principle by use of lyme disease sera
    Carl V Hamby
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Clin Diagn Lab Immunol 12:801-7. 2005
    ....
  3. pmc SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model
    Rachel Ackerman
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Toxins (Basel) 2:2242-57. 2010
    ..We hypothesize that SLT-VEGF could be a promising adjuvant therapy to inhibit or prevent outgrowth of metastatic foci after excision of aggressive primary melanoma lesions...

Research Grants1

  1. SLT-VEGF for anti-angiogenic therapy of melanoma
    Carl Hamby; Fiscal Year: 2006
    ..The information obtained in this study will provide a rational basis for deciding whether SLT-VEGF alone or combined with IFN-alpha will be suitable for further development and testing in clinical trials with human patients. ..